R

Redhill Biopharma Ltd

D
RDHL
USD
-0.14
(-1.6867%)
Market Closed
184.000
Volume
-1.1
EPS
-
Div Yield
-0.026964
P/E
10,449,198.24
Market Cap
Today
-1.6867%
1 Week
-0.609%
1 Month
0.617%
6 Months
-28.858%
12 Months
-5.474%
Year To Date
-77.490%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
GILD
GILD
6.36
(6.9463%)
USD
N
NNVC
-0.01
(-0.6711%)
USD
MRNA
MRNA
-1.49
(-2.8776%)
USD
V
VSTM
-0.27
(-6.9858%)
USD
B
BCRX
-0.06
(-0.7767%)
USD
REGN
REGN
-3.78
(-0.4561%)
USD
PFE
PFE
0.135
(0.4941%)
USD
MRK
MRK
0.46
(0.4567%)
USD
AZN
AZN
0.835
(1.308%)
USD
I
INO
-0.13
(-2.2968%)
USD
B
BNTX
0.99
(0.9269%)
USD

Title:
Redhill Biopharma Ltd

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company alsocommercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
Do you need help or have a question?
Contact Us